Pharma
Curative Therapeutics

There are only a small number of diseases in which intervention at a single point, common across all patients, can sufficiently and persistently alter the system towards a healthy state. Most diseases consist of a complex set of dynamic failures from genetics and epigenetics to neural activity: these differ across patients, within patients and over time. Trials often fail because the models used to demonstrate effectiveness in preclinical studies don’t accurately reflect the underlying causes, which can vary substantially across diseases and patients, and endpoints in trials often measure symptoms.
Our approach to creating curative therapeutic companies focuses on four themes: effectively leveraging computational approaches to address complexity; developing therapeutics that can compute in-vivo and respond dynamically to the changing internal environment; creating better systems, models and analytics to support therapeutic discovery and development; and a focus on the root cause, including fixing and buffering molecular level damage, fixing broken or unhelpful messaging and signalling pathways, correcting errors at every level of gene expression and modifying the state of cells to drive regeneration.
Areas of venture creation:
Available opportunities
Our companies
Content

-
pharmaceuticals
-
Neurofibromatosis
Gene Therapy for Neurofibromatosis - the Path to a Cure
Despite being among the most common genetic disorders worldwide (1 in ~2500 births collectively) the NF field has sadly been overlooked for decades. Yet it is difficult to understand why, given the huge unmet need and extremely limited treatment options – none of which offer curative potential for patients. Gene therapy offers the path towards a cure. In this article, we outline the nature of the challenge, why now is the right time to solve it, and explore the unanswered questions we'd like to address through venture creation.

-
pharmaceuticals
-
Enedra Therapeutics
Leading Cancer Biologists and Entrepreneurs Join Enedra Therapeutics as Co-Founders
Enedra Therapeutics, a therapeutics company within the Deep Science Ventures portfolio, announces that it is adding a number of seasoned industry executives as co-founders, bringing extensive expertise in cancer biology, drug discovery and corporate strategy to the team.

-
pharmaceuticals
-
Inflammatory disease
Why are there no cures for inflammatory disease – and can tolerance solve it?
Despite tremendous unmet need, there are still no cures for inflammatory disease. Existing therapies fail for known reasons – yet nobody has thus far created therapeutics that fulfil all the necessary requirements. We need to find ways to turn off the causal upstream sources of inflammation rather than simply mopping up downstream inflammatory signals.